Je PRA Health Sciences dividenda varna?
PRA Health Sciences povečuje dividendo že 0 let.
V zadnjih 10 letih je PRA Health Sciences to vrednost povečal za 0 % letno.
V petletnem obdobju se je izplačilo povečalo za 0 %.
Analitiki za tekoče poslovno leto pričakujejo rast Znižanje dividend za −100,000%.
PRA Health Sciences Aktienanalyse
Kaj počne PRA Health Sciences?
PRA Health Sciences Inc. is a globally operating company for clinical research that was founded in 1982 and is headquartered in Raleigh, North Carolina. It specializes in supporting pharmaceutical and medical device manufacturers in the development and approval of drugs and medical devices.
The business model of PRA Health Sciences is based on providing services throughout the entire clinical development process. This includes planning and conducting clinical trials, monitoring study centers, data collection and management, as well as statistics and medical consulting.
The company's activities are divided into several divisions that focus on different areas of clinical development. The "Early Development Services" division offers services for the early clinical development of drugs and medical devices, including the conduct of Phase I studies and support for proof-of-concept studies. The "Clinical Development Services" division offers services for the later clinical development of drugs and medical devices, including the conduct of Phase II to Phase IV studies.
The "Strategic Solutions" division offers a wide range of services for the entire clinical development process, including consulting, data analysis and interpretation, as well as the integration of technologies such as electronic medical records software. The "Product Registration" division offers services for the approval of drugs and medical devices, including support for submission of applications and the provision of regulatory affairs consulting services.
One of the products offered by PRA Health Sciences is the "Lifetree Clinical Research" software platform, which is used for the management of clinical trials. Lifetree offers features for data management, project collaboration, and reporting, allowing users to access extensive amounts of data in real-time.
PRA Health Sciences has a broad customer base including pharmaceutical and biotech companies, medical device manufacturers, and contract research organizations. The company has offices in more than 80 countries and employs approximately 18,000 people worldwide.
In 2020, PRA Health Sciences was acquired by ICON plc, another globally operating company for clinical research. The acquisition is intended to expand ICON's global presence and service areas, enabling the company to offer a broader range of services in clinical development to its clients.
Overall, PRA Health Sciences is a company for clinical research that offers a wide range of services for the development of drugs and medical devices. With its broad customer base, comprehensive range of services, and global presence, it is an important component of the clinical research industry and is expected to continue to play a crucial role in the development of new drugs and medical devices. PRA Health Sciences je eno izmed najbolj priljubljenih podjetij na Eulerpool.com.Delniški varčevalni načrti ponujajo privlačno možnost za vlagatelje, da dolgoročno zgradijo premoženje. Eden glavnih prednosti je tako imenovani učinek povprečenja stroškov: Z rednim vlaganjem fiksnega zneska v delnice ali delniške sklade se avtomatsko kupi več enot, ko so cene nizke, in manj, ko so visoke. To lahko vodi do ugodnejše povprečne cene na enoto s časom. Poleg tega delniški varčevalni načrti omogočajo tudi malim vlagateljem dostop do dragih delnic, saj se lahko pridružijo že z majhnimi zneski. Redna investicija tudi spodbuja disciplinirano investicijsko strategijo in pomaga izogibati se čustvenim odločitvam, kot so impulzivno kupovanje ali prodaja. Poleg tega vlagatelji profitirajo od potencialne rasti vrednosti delnic kot tudi od izplačil dividend, ki se lahko reinvestirajo, kar povečuje učinek obrestnega obrestovanja in s tem rast investiranega kapitala.